ArticleACS chemical neuroscience2013
Future directions for serotonin and antidepressants.
Article in ACS chemical neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Article
- Proteochemometric Modeling Identifies Chemically Diverse Norepinephrine Transporter Inhibitors.Journal of chemical information and modeling · 2023Article
- TheFrontiers in genetics · 2021Article
- A Photoswitchable Inhibitor of the Human Serotonin Transporter.ACS chemical neuroscience · 2020Article
- Chronic Fluoxetine Impairs the Effects of 5-HTFrontiers in pharmacology · 2020Article
- Review
- The Effect of Citalopram on Genome-Wide DNA Methylation of Human Cells.International journal of genomics · 2018Article
- Beneficial effects of trimetazidine on expression of serotonin and serotonin transporter in rats with myocardial infarction and depression.Neuropsychiatric disease and treatment · 2018Article
- Serotonin and brain function: a tale of two receptors.Journal of psychopharmacology (Oxford, England) · 2017Review
- Evaluation and Management of SCI-Associated Pain.Current pain and headache reports · 2016Review
- Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study.Scientific reports · 2016Article
- Synthesis and evaluation of new 1,5-diaryl-3-[4-(methyl-sulfonyl)phenyl]-4,5-dihydro-1H-pyrazole derivatives as potential antidepressant agents.Molecules (Basel, Switzerland) · 2015Article
- Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine.ACS medicinal chemistry letters · 2014Article
- What's old is new.ACS chemical neuroscience · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the widespread use of antidepressant medications that block serotonin (5-hydroxytryptamine; 5-HT) and/or norepinephrine (NE) transporters, such as SSRIs (selective serotonin reuptake inhibitors) or SNRIs (serotonin and norepinephrine reuptake inhibitors), the underlying neurobiological basis of action of these agents is poorly understood. Increases in serotonergic function are hypothesized to have beneficial effects on depressive symptoms. However, which of the 14 different neuronal receptors sensitive to 5-HT accounts for the therapeutic effects of SSRIs and SNRIs remains undetermined. The development of drugs that activate or block specific 5-HT receptors may help to circumvent the two main limitations of current antidepressants: low efficacy and delayed onset of therapeutic action. What follows is a short summary of the author's views on this matter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.